文献速递角膜与眼表疾病

新型BMP7与HGF联合基因疗法在体内诱导肌成纤维细胞选择性凋亡并减少角膜混浊

Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

研究在兔碱烧伤角膜纤维化模型及人角膜成纤维细胞/肌成纤维细胞体外模型中,测试骨形态发生蛋白7(BMP7)与肝细胞生长因子(HGF)联合基因疗法的效果。结果显示PEI2-GNP介导的BMP7+HGF基因疗法显著降低兔角膜纤维化(Fantes评分0.6 vs 3.3,P<0.001)并减少肌成纤维细胞83%(P<0.001),局部点眼未见眼毒性。

要点

  • 兔碱烧伤角膜接受BMP7+HGF基因治疗后Fantes评分为0.6,对照为3.3(P<0.001)。
  • BMP7+HGF治疗组肌成纤维细胞较对照减少83%(P<0.001),促纤维化基因mRNA显著降低。
  • 重组HGF诱导角膜肌成纤维细胞凋亡而不诱导成纤维细胞凋亡,局部治疗未见眼毒性。

核心结论

  • 局部点眼BMP7+HGF基因疗法可治疗兔角膜纤维化并在体内恢复角膜透明度,减轻过度愈合并使肌成纤维细胞发生选择性凋亡。

研究设计与样本

  • 研究使用18只新西兰白兔,通过碱烧伤制作角膜纤维化模型,伤后24小时分组接受局部治疗。
  • 三组各6只眼分别接受平衡盐溶液(BSS)、聚乙烯亚胺偶联金纳米颗粒(PEI2-GNP)裸质粒或表达BMP7与HGF基因的PEI2-GNP质粒。
  • 采用供体人角膜获取原代人角膜成纤维细胞和肌成纤维细胞进行机制研究。
  • 通过裂隙灯显微镜、立体显微镜、实时定量PCR、免疫荧光、TUNEL、改良MacDonald-Shadduck评分系统和Draize试验评估抗纤维化效果与眼部安全性。

主要发现

  • 活体兔角膜中PEI2-GNP介导的BMP7+HGF基因治疗显著降低角膜纤维化,Fantes评分在BMP7+HGF治疗眼为0.6,对照治疗组为3.3(P<0.001)。
  • BMP7+HGF治疗角膜的促纤维化基因mRNA水平较对照角膜显著降低:α-SMA为3.2倍(P<0.01)、纤连蛋白为2.3倍(P<0.01)、I型胶原为2.1倍(P<0.01)、III型胶原为1.6倍(P<0.01)、IV型胶原为1.9倍(P<0.01)。
  • BMP7+HGF治疗角膜的肌成纤维细胞较对照显著减少83%(P<0.001)。
  • PEI2-GNP导入每微克DNA超过10^4个BMP7和HGF基因拷贝。
  • 重组HGF诱导角膜肌成纤维细胞凋亡而不诱导成纤维细胞凋亡,局部点眼BMP7+HGF治疗未见眼毒性。

关键数值与推荐

  • Fantes评分:BMP7+HGF治疗眼为0.6,对照治疗组为3.3(P<0.001)。
  • α-SMA mRNA降低3.2倍(P<0.01),纤连蛋白降低2.3倍(P<0.01),I型胶原降低2.1倍(P<0.01),III型胶原降低1.6倍(P<0.01),IV型胶原降低1.9倍(P<0.01),均为BMP7+HGF治疗角膜较对照角膜。
  • 肌成纤维细胞减少83%(P<0.001),为BMP7+HGF治疗角膜较对照角膜。
  • PEI2-GNP导入每微克DNA超过10^4个BMP7和HGF基因拷贝。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We tested the potential of bone morphogenic protein 7 (BMP7) and hepatocyte growth factor (HGF) combination gene therapy to treat preformed corneal fibrosis using established rabbit in vivo and human in vitro models. METHODS: Eighteen New Zealand White rabbits were used. Corneal fibrosis was produced by alkali injury. Twenty-four hours after scar formation, cornea received topically either balanced salt solution (BSS; n = 6), polyethylenimine-conjugated gold nanoparticle (PEI2-GNP)-naked plasmid (n = 6) or PEI2-GNP plasmids expressing BMP7 and HGF genes (n = 6). Donor human corneas were used to obtain primary human corneal fibroblasts and myofibroblasts for mechanistic studies. Gene therapy effects on corneal fibrosis and ocular safety were evaluated by slit-lamp microscope, stereo microscopes, quantitative real-time PCR, immunofluorescence, TUNEL, modified MacDonald-Shadduck scoring system, and Draize tests. RESULTS: PEI2-GNP-mediated BMP7+HGF gene therapy significantly decreased corneal fibrosis in live rabbits in vivo (Fantes scale was 0.6 in BMP7+HGF-treated eyes compared to 3.3 in -therapy group; P < 0.001). Corneas that received BMP7+HGF demonstrated significantly reduced mRNA levels of profibrotic genes: α-SMA (3.2-fold; P < 0.01), fibronectin (2.3-fold, P < 0.01), collagen I (2.1-fold, P < 0.01), collagen III (1.6-fold, P < 0.01), and collagen IV (1.9-fold, P < 0.01) compared to the -therapy corneas. Furthermore, BMP7+HGF-treated corneas showed significantly fewer myofibroblasts compared to the -therapy controls (83%; P < 0.001). The PEI2-GNP introduced >104 gene copies per microgram DNA of BMP7 and HGF genes. The recombinant HGF rendered apoptosis in corneal myofibroblasts but not in fibroblasts. Localized topical BMP7+HGF therapy showed no ocular toxicity. CONCLUSIONS: Localized topical BMP7+HGF gene therapy treats corneal fibrosis and restores transparency in vivo mitigating excessive healing and rendering selective apoptosis in myofibroblasts.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Gupta S, Fink MK, Ghosh A, et al. Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo. Invest Ophthalmol Vis Sci. 2018. PMID: 29490341. doi:10.1167/iovs.17-23308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。